ADMA Biologics, Inc. (NASDAQ:ADMA) Shares Acquired by Healthcare of Ontario Pension Plan Trust Fund

Healthcare of Ontario Pension Plan Trust Fund increased its stake in ADMA Biologics, Inc. (NASDAQ:ADMA) by 13.9% during the third quarter, HoldingsChannel.com reports. The fund owned 658,900 shares of the biotechnology company’s stock after buying an additional 80,400 shares during the period. Healthcare of Ontario Pension Plan Trust Fund’s holdings in ADMA Biologics were worth $13,171,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the stock. BNP Paribas Financial Markets grew its holdings in shares of ADMA Biologics by 12.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 750,788 shares of the biotechnology company’s stock worth $15,008,000 after acquiring an additional 85,250 shares during the last quarter. FMR LLC grew its holdings in shares of ADMA Biologics by 3.7% in the 3rd quarter. FMR LLC now owns 1,944,831 shares of the biotechnology company’s stock worth $38,877,000 after acquiring an additional 68,881 shares during the last quarter. Bank of Montreal Can boosted its position in shares of ADMA Biologics by 30.6% in the third quarter. Bank of Montreal Can now owns 2,086,322 shares of the biotechnology company’s stock worth $40,443,000 after buying an additional 489,320 shares during the period. Harvest Fund Management Co. Ltd acquired a new stake in shares of ADMA Biologics in the third quarter worth $62,000. Finally, Larson Financial Group LLC acquired a new stake in shares of ADMA Biologics in the third quarter worth $31,000. 75.68% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have recently commented on the company. Raymond James raised their target price on ADMA Biologics from $18.00 to $25.00 and gave the stock a “strong-buy” rating in a research report on Friday, November 8th. HC Wainwright raised their target price on ADMA Biologics from $18.00 to $26.00 and gave the stock a “buy” rating in a research report on Friday, November 8th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $20.00 target price on shares of ADMA Biologics in a research report on Friday, September 20th.

Insider Buying and Selling at ADMA Biologics

In other news, Director Lawrence P. Guiheen sold 9,000 shares of the company’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $18.47, for a total transaction of $166,230.00. Following the completion of the sale, the director now owns 153,941 shares in the company, valued at approximately $2,843,290.27. This represents a 5.52 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Brad L. Tade sold 15,000 shares of the company’s stock in a transaction dated Friday, November 22nd. The stock was sold at an average price of $21.15, for a total value of $317,250.00. Following the sale, the chief financial officer now owns 199,433 shares of the company’s stock, valued at approximately $4,218,007.95. This trade represents a 7.00 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 3.70% of the company’s stock.

ADMA Biologics Stock Performance

Shares of NASDAQ ADMA opened at $21.83 on Friday. The business’s 50-day moving average price is $19.08 and its two-hundred day moving average price is $15.23. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26. ADMA Biologics, Inc. has a one year low of $3.60 and a one year high of $23.64. The company has a market capitalization of $5.16 billion, a P/E ratio of 77.96 and a beta of 0.64.

ADMA Biologics (NASDAQ:ADMA) last issued its earnings results on Thursday, November 7th. The biotechnology company reported $0.15 EPS for the quarter, beating analysts’ consensus estimates of $0.13 by $0.02. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. The firm had revenue of $119.84 million for the quarter, compared to the consensus estimate of $107.25 million. During the same quarter in the previous year, the company posted $0.01 earnings per share. Analysts anticipate that ADMA Biologics, Inc. will post 0.52 earnings per share for the current fiscal year.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.